View Item 

Show simple item record

Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
dc.contributor.authorEsagian, Stepan M.
dc.contributor.authorKhaki, Ali Raza
dc.contributor.authorDiamantopoulos, Leonidas N.
dc.contributor.authorCarril‐ajuria, Lucia
dc.contributor.authorCastellano, Daniel
dc.contributor.authorDe Kouchkovsky, Ivan
dc.contributor.authorPark, Joseph J.
dc.contributor.authorAlva, Ajjai
dc.contributor.authorBilen, Mehmet A.
dc.contributor.authorStewart, Tyler F.
dc.contributor.authorMcKay, Rana R.
dc.contributor.authorSantos, Victor S.
dc.contributor.authorAgarwal, Neeraj
dc.contributor.authorJain, Jayanshu
dc.contributor.authorZakharia, Yousef
dc.contributor.authorMorales‐barrera, Rafael
dc.contributor.authorDevitt, Michael E.
dc.contributor.authorNelson, Ariel
dc.contributor.authorHoimes, Christopher J.
dc.contributor.authorShreck, Evan
dc.contributor.authorGartrell, Benjamin A.
dc.contributor.authorSankin, Alex
dc.contributor.authorTripathi, Abhishek
dc.contributor.authorZakopoulou, Roubini
dc.contributor.authorBamias, Aristotelis
dc.contributor.authorRodriguez‐vida, Alejo
dc.contributor.authorDrakaki, Alexandra
dc.contributor.authorLiu, Sandy
dc.contributor.authorKumar, Vivek
dc.contributor.authorLythgoe, Mark P.
dc.contributor.authorPinato, David J.
dc.contributor.authorMurgic, Jure
dc.contributor.authorFröbe, Ana
dc.contributor.authorJoshi, Monika
dc.contributor.authorIsaacsson Velho, Pedro
dc.contributor.authorHahn, Noah
dc.contributor.authorAlonso Buznego, Lucia
dc.contributor.authorDuran, Ignacio
dc.contributor.authorMoses, Marcus
dc.contributor.authorBarata, Pedro
dc.contributor.authorGalsky, Matthew D.
dc.contributor.authorSonpavde, Guru
dc.contributor.authorYu, Evan Y.
dc.contributor.authorMsaouel, Pavlos
dc.contributor.authorKoshkin, Vadim S.
dc.contributor.authorGrivas, Petros
dc.date.accessioned2021-08-03T18:14:28Z
dc.date.available2022-09-03 14:14:27en
dc.date.available2021-08-03T18:14:28Z
dc.date.issued2021-08
dc.identifier.citationEsagian, Stepan M.; Khaki, Ali Raza; Diamantopoulos, Leonidas N.; Carril‐ajuria, Lucia ; Castellano, Daniel; De Kouchkovsky, Ivan; Park, Joseph J.; Alva, Ajjai; Bilen, Mehmet A.; Stewart, Tyler F.; McKay, Rana R.; Santos, Victor S.; Agarwal, Neeraj; Jain, Jayanshu; Zakharia, Yousef; Morales‐barrera, Rafael ; Devitt, Michael E.; Nelson, Ariel; Hoimes, Christopher J.; Shreck, Evan; Gartrell, Benjamin A.; Sankin, Alex; Tripathi, Abhishek; Zakopoulou, Roubini; Bamias, Aristotelis; Rodriguez‐vida, Alejo ; Drakaki, Alexandra; Liu, Sandy; Kumar, Vivek; Lythgoe, Mark P.; Pinato, David J.; Murgic, Jure; Fröbe, Ana ; Joshi, Monika; Isaacsson Velho, Pedro; Hahn, Noah; Alonso Buznego, Lucia; Duran, Ignacio; Moses, Marcus; Barata, Pedro; Galsky, Matthew D.; Sonpavde, Guru; Yu, Evan Y.; Msaouel, Pavlos; Koshkin, Vadim S.; Grivas, Petros (2021). "Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes." BJU International (2): 196-205.
dc.identifier.issn1464-4096
dc.identifier.issn1464-410X
dc.identifier.urihttps://hdl.handle.net/2027.42/168446
dc.publisherWiley Periodicals, Inc.
dc.subject.otherupper tract urothelial cancer
dc.subject.othervariant histology
dc.subject.other#utuc
dc.subject.other#uroonc
dc.subject.otherbladder cancer
dc.subject.othercheckpoint inhibitor
dc.subject.otherimmunotherapy
dc.titleImmune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168446/1/bju15324.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168446/2/bju15324_am.pdf
dc.identifier.doi10.1111/bju.15324
dc.identifier.sourceBJU International
dc.identifier.citedreferenceEuropean Cancer Information System. Cancer burden statistics and trends across Europe | ECIS [Internet]. Available at: https://ecis.jrc.ec.europa.eu/index.php. Accessed September 2020
dc.identifier.citedreferenceNational Cancer Institute. Bladder Cancer - Cancer Stat Facts [Internet]. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed September 2020
dc.identifier.citedreferenceKhaki AR, Li A, Diamantopoulos LN et al. Impact of performance status on treatment outcomes: a real- world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer 2020; 126: 1208 - 16
dc.identifier.citedreferencePalmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient- to- patient variability without drug additivity or synergy. Cell 2017; 171: 1678 - 91.e13
dc.identifier.citedreferenceGrivas P, Sternberg CN, Agarwal N et al. 796TiP TROPHY- U- 01 Cohort 3: sacituzumab govitecan (SG) and pembrolizumab (pembro) in patients (pts) with progression or recurrence of metastatic urothelial cancer (mUC) after platinum (PLT)- based therapy. Ann Oncol 2020; 1: S604 - S605
dc.identifier.citedreferenceGrivas P, Drakaki A, Friedlander TW, Sonpavde G. Conceptual framework for therapeutic development beyond anti- PD- 1/PD- L1 in urothelial cancer. Am Soc Clin Oncol Educ B 2019; 39: 284 - 300
dc.identifier.citedreferenceKhaki AR, Agarwal N, Pal SK, Grivas P. Immunotherapy- based combination strategies for advanced urothelial cancer: a long quest. Cancer 2020; 126: 4446 - 50
dc.identifier.citedreferenceBarata PC, Koshkin VS, Funchain P et al. Next- generation sequencing (NGS) of cell- free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol 2017; 28: 2458 - 63
dc.identifier.citedreferenceGrivas P, Lalani AK, Pond GR et al. Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: a pilot study. Eur Urol Oncol 2020; 3: 695 - 9
dc.identifier.citedreferenceChristensen E, Birkenkamp- Demtröder K, Sethi H et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra- deep sequencing of plasma cell- free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 2019; 37: 1547 - 57
dc.identifier.citedreferencePal SK, Bajorin D, Dizman N et al. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell- free DNA results. Cancer 2020; 126: 2597 - 606
dc.identifier.citedreferenceNassar AH, Mouw KW, Jegede O et al. A model combining clinical and genomic factors to predict response to PD- 1/PD- L1 blockade in advanced urothelial carcinoma. Br J Cancer 2020; 122: 555 - 63
dc.identifier.citedreferenceSonpavde G, Manitz J, Gao C et al. Five- factor prognostic model for survival of post- platinum patients with metastatic urothelial carcinoma receiving PD- L1 inhibitors. J Urol 2020; 204: 1173 - 9
dc.identifier.citedreferencePowles T, Walker J, Andrew Williams J, Bellmunt J. The evolving role of PD- L1 testing in patients with metastatic urothelial carcinoma. Cancer Treat Rev 2020; 82: 101925
dc.identifier.citedreferenceLe DT, Uram JN, Wang H et al. PD- 1 blockade in tumors with mismatch- repair deficiency. N Engl J Med 2015; 372: 2509 - 20
dc.identifier.citedreferenceCatto JW, Azzouzi AR, Amira N et al. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene 2003; 22: 8699 - 706
dc.identifier.citedreferenceSantiago- Walker AE, Chen F, Loriot Y et al. Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti- PD- (L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC). J Clin Oncol 2019; 37 ( Suppl. ): 419
dc.identifier.citedreferenceWang L, Gong Y, Saci A et al. Fibroblast growth factor receptor 3 alterations and response to PD- 1/PD- L1 blockade in patients with metastatic urothelial cancer. Eur Urol 2019; 76: 599 - 603
dc.identifier.citedreferenceMoss TJ, Qi Y, Xi L et al. Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol 2017; 72: 641 - 9
dc.identifier.citedreferenceAudenet F, Isharwal S, Cha EK et al. Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. Clin Cancer Res 2019; 25: 967 - 76
dc.identifier.citedreferenceSweis RF, Spranger S, Bao R et al. Molecular drivers of the non- T- cell- inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res 2016; 4: 563 - 8
dc.identifier.citedreferenceGajewski TF. Next hurdle in cancer immunorapy: overcoming non- T- cell- inflamed tumor microenvironment. Semin Oncol 2015; 42: 663 - 71.
dc.identifier.citedreferenceSharma P, Shen Y, Wen S et al. CD8 tumor- infiltrating lymphocytes are predictive of survival in muscle- invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007; 104: 3967 - 72
dc.identifier.citedreferenceLi H, Zhang Q, Shuman L et al. Evaluation of PD- L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. Sci Rep 2020; 10: 1439
dc.identifier.citedreferenceRobinson BD, Vlachostergios PJ, Bhinder B et al. Upper tract urothelial carcinoma has a luminal- papillary T- cell depleted contexture and activated FGFR3 signaling. Nat Commun 2019; 10: 2977
dc.identifier.citedreferenceMiller NJ, Khaki AR, Diamantopoulos LN et al. Histological subtypes and response to PD- 1/PD- L1 blockade in advanced urothelial cancer: a retrospective study. J Urol 2020; 204: 63 - 70
dc.identifier.citedreferenceMcGregor BA, Campbell MT, Xie W et al. Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers. J Clin Oncol 2020; 38 ( Suppl. ): 5018
dc.identifier.citedreferenceNecchi A, Madison R, Pal SK et al. Comprehensive genomic profiling of upper- tract and bladder urothelial carcinoma. Eur Urol Focus 2020 [Online ahead of print]. https://doi.org/10.1016/j.euf.2020.08.001
dc.identifier.citedreferenceGalsky MD, Banchereau R, Kadel EE et al. Biological features and clinical outcomes in atezolizumab (atezo)- treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC). Ann Oncol 2018; 29: viii321
dc.identifier.citedreferenceBellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum- containing regimens. J Clin Oncol 2010; 28: 1850 - 5
dc.identifier.citedreferenceHarris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)- A metadata- driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377 - 81
dc.identifier.citedreferenceSternberg CN, Loriot Y, James N et al. Primary results from SAUL, a multinational single- arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol 2019; 76: 73 - 81
dc.identifier.citedreferencePatel MR, Ellerton J, Infante JR et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open- label, phase 1 trial. Lancet Oncol 2018; 19: 51 - 64
dc.identifier.citedreferenceSharma P, Retz M, Siefker- Radtke A et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single- arm, phase 2 trial. Lancet Oncol 2017; 18: 312 - 22
dc.identifier.citedreferenceBalar AV, Castellano D, O- Donnell PH et al. First- line pembrolizumab in cisplatin- ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE- 052): a multicentre, single- arm, phase 2 study. Lancet Oncol 2017; 18: 1483 - 92
dc.identifier.citedreferenceGalsky MD, Arija Jà , Bamias A et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo- controlled phase 3 trial. Lancet 2020; 395: 1547 - 57
dc.identifier.citedreferencePowles T, Durán I, van der Heijden MS et al. Atezolizumab versus chemotherapy in patients with platinum- treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open- label, phase 3 randomised controlled trial. Lancet 2018; 391: 748 - 57
dc.identifier.citedreferenceBalar AV, Galsky MD, Rosenberg JE et al. Atezolizumab as first- line treatment in cisplatin- ineligible patients with locally advanced and metastatic urothelial carcinoma: a single- arm, multicentre, phase 2 trial. Lancet 2017; 389: 67 - 76
dc.identifier.citedreferenceRosenberg JE, Hoffman- Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum- based chemotherapy: A single- arm, multicentre, phase 2 trial. Lancet 2016; 387: 1909 - 20
dc.identifier.citedreferencePowles T, Park SH, Voog E et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020; 383: 1218 - 30
dc.identifier.citedreferenceBellmunt J, de Wit R, Vaughn DJ et al. Pembrolizumab as second- line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015 - 26
dc.identifier.citedreferenceGopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag 2018; 14: 1019 - 40
dc.identifier.citedreferenceShao IH, Chang YH, Pang ST. Recent advances in upper tract urothelial carcinomas: from bench to clinics. Int J Urol 2019; 26: 148 - 59
dc.identifier.citedreferenceLeow JJ, Chong KT, Chang SL, Bellmunt J Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open 2017; 1: e000126
dc.identifier.citedreferenceAgarwal N, Pal SK, Hahn AW et al. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer 2018; 124: 2115 - 24
dc.identifier.citedreferenceWinters BR, De Sarkar N, Arora S et al. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. JCI Insight 2019; 5: e128728
dc.identifier.citedreferenceGreen DA, Rink M, Xylinas E et al. Urothelial carcinoma of the bladder and the upper tract: Disparate twins. J Urol 2013; 189: 1214 - 21
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bju15324.pdf
Size:
434.2KB
Format:
PDF
View/Open
Name:
bju15324_am.pdf
Size:
394.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.